FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367668859> ?p ?o ?g. }

• W4367668859 endingPage "406" @default.
• W4367668859 startingPage "395" @default.
• W4367668859 abstract "Introduction Cold agglutinin disease (CAD) is a difficult-to-treat autoimmune hemolytic anemia and B cell lymphoproliferative disorder associated with fatigue, acrocyanosis, and a risk of thromboembolic events. Cold-induced binding of autoantibody agglutinates red blood cells and triggers the classical complement pathway, leading to predominantly extravascular hemolysis.Areas covered This review summarizes clinical and experimental antibody-based treatments for CAD and analyzes the risks and benefits of B cell and complement directed therapies, and discusses potential future treatments for CAD.Expert opinion Conventional treatment of CAD includes a B cell targeted treatment approach with rituximab, yielding only limited treatment success. The addition of a cytotoxic agent (e.g. bendamustine) increases efficacy, but this is accompanied by an increased risk of neutropenia and infection. Novel complement directed therapies have emerged and were shown to have good efficacy against hemolysis and safety profiles but are expensive and unable to address circulatory symptoms. Complement inhibition with sutimlimab may be used as a bridging strategy until B cell directed therapy with rituximab takes effect or continued indefinitely if needed. Future antibody-based treatment approaches for CAD involve the further development of complement directed antibodies, a combination of rituximab and bortezomib, and daratumumab. Non-antibody based prospective treatments may include the use of Bruton tyrosine kinase inhibitors." @default.
• W4367668859 created "2023-05-03" @default.
• W4367668859 creator A5032982255 @default.
• W4367668859 creator A5079980990 @default.
• W4367668859 creator A5080941679 @default.
• W4367668859 date "2023-05-04" @default.
• W4367668859 modified "2023-10-14" @default.
• W4367668859 title "Monoclonal antibodies for treatment of cold agglutinin disease" @default.
• W4367668859 cites W1963996170 @default.
• W4367668859 cites W1974398400 @default.
• W4367668859 cites W1975338840 @default.
• W4367668859 cites W1981933562 @default.
• W4367668859 cites W1984204316 @default.
• W4367668859 cites W1988198298 @default.
• W4367668859 cites W2005415797 @default.
• W4367668859 cites W2011261778 @default.
• W4367668859 cites W2016377751 @default.
• W4367668859 cites W2029974213 @default.
• W4367668859 cites W2031501023 @default.
• W4367668859 cites W2046234363 @default.
• W4367668859 cites W2055174107 @default.
• W4367668859 cites W2091704080 @default.
• W4367668859 cites W2106621818 @default.
• W4367668859 cites W2112476236 @default.
• W4367668859 cites W2116806859 @default.
• W4367668859 cites W2118404859 @default.
• W4367668859 cites W2133192145 @default.
• W4367668859 cites W2169209759 @default.
• W4367668859 cites W2193278586 @default.
• W4367668859 cites W2201952665 @default.
• W4367668859 cites W2273784326 @default.
• W4367668859 cites W2396715364 @default.
• W4367668859 cites W2529243499 @default.
• W4367668859 cites W2619999402 @default.
• W4367668859 cites W2620106135 @default.
• W4367668859 cites W2621219771 @default.
• W4367668859 cites W2624644262 @default.
• W4367668859 cites W2775053621 @default.
• W4367668859 cites W2777932111 @default.
• W4367668859 cites W2781660650 @default.
• W4367668859 cites W2797165009 @default.
• W4367668859 cites W2802582736 @default.
• W4367668859 cites W2808176284 @default.
• W4367668859 cites W2895395495 @default.
• W4367668859 cites W2900280452 @default.
• W4367668859 cites W2905576105 @default.
• W4367668859 cites W2909790825 @default.
• W4367668859 cites W2911948547 @default.
• W4367668859 cites W2912694118 @default.
• W4367668859 cites W2937199787 @default.
• W4367668859 cites W2972737609 @default.
• W4367668859 cites W2980964548 @default.
• W4367668859 cites W2994304950 @default.
• W4367668859 cites W3011335798 @default.
• W4367668859 cites W3011607877 @default.
• W4367668859 cites W3015421834 @default.
• W4367668859 cites W3015765699 @default.
• W4367668859 cites W3022133501 @default.
• W4367668859 cites W3022726062 @default.
• W4367668859 cites W3041728583 @default.
• W4367668859 cites W3086890593 @default.
• W4367668859 cites W3124977663 @default.
• W4367668859 cites W3136167138 @default.
• W4367668859 cites W3144481484 @default.
• W4367668859 cites W3156633970 @default.
• W4367668859 cites W3183565120 @default.
• W4367668859 cites W3197919130 @default.
• W4367668859 cites W3204455148 @default.
• W4367668859 cites W3211532806 @default.
• W4367668859 cites W4210402127 @default.
• W4367668859 cites W4220944640 @default.
• W4367668859 cites W4223452661 @default.
• W4367668859 cites W4229364881 @default.
• W4367668859 cites W4254892135 @default.
• W4367668859 cites W4281625438 @default.
• W4367668859 cites W4281636030 @default.
• W4367668859 cites W4281945974 @default.
• W4367668859 cites W4283381496 @default.
• W4367668859 cites W4293387263 @default.
• W4367668859 cites W4297463110 @default.
• W4367668859 cites W4308054824 @default.
• W4367668859 cites W4317532114 @default.
• W4367668859 cites W5287291 @default.
• W4367668859 doi "https://doi.org/10.1080/14712598.2023.2209265" @default.
• W4367668859 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37128907" @default.
• W4367668859 hasPublicationYear "2023" @default.
• W4367668859 type Work @default.
• W4367668859 citedByCount "0" @default.
• W4367668859 crossrefType "journal-article" @default.
• W4367668859 hasAuthorship W4367668859A5032982255 @default.
• W4367668859 hasAuthorship W4367668859A5079980990 @default.
• W4367668859 hasAuthorship W4367668859A5080941679 @default.
• W4367668859 hasConcept C111684460 @default.
• W4367668859 hasConcept C159654299 @default.
• W4367668859 hasConcept C163764329 @default.
• W4367668859 hasConcept C203014093 @default.
• W4367668859 hasConcept C2777385706 @default.
• W4367668859 hasConcept C2777726029 @default.

• next